Form 4: OptimizeRx Executive Stephen L. Silvestro Reports Stock Transactions
SEC Form 4 Filing
Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 1, 2025, Stephen L. Silvestro, Chief Commercial Officer of OptimizeRx Corp, had 1,928 restricted stock units vest.
- These units converted into common stock.
- 572 shares were withheld by the issuer to cover the reporting person's tax obligations at a price of $5.18 per share.
- Following these transactions, Silvestro directly owns 121,314 shares of OptimizeRx Corp.
- The filing clarifies that it should not be construed as an admission of beneficial ownership or a legal requirement to file.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard executive compensation practices; it doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transaction affects the reporting person's holdings in the company.
- The tax withholding impacts the company's cash flow.
Key Dates
| Date | Description |
|---|---|
| 03/01/2023 | First anniversary of the grant date of the restricted stock units, marking the beginning of vesting in three equal annual installments. |
| 03/01/2025 | Date of transaction: vesting of restricted stock units and tax withholding. |
| 03/04/2025 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.